0M4.F Stock Analysis
0M
Uncovered
Mersana Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2017-06-28. The firm lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase I/II umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. XMT-1592, its second ADC product candidate targeting NaPi2b-expressing tumors, is developed by using its customizable and homogeneous Dolasynthen platform and is in the dose exploration portion of a Phase I clinical trial. Its early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting an epitope of human epidermal growth factor receptor 2.